ArticleInternational journal of general medicine2022
IGFBP5 is Upregulated and Associated with Poor Prognosis in Colorectal Cancer.
Article in International journal of general medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Unravelling the effects of selective estrogen receptor modulators on colorectal cancer: a prognostic role for insulin-like growth factor binding protein-5.Clinical science (London, England : 1979) · 2026Article
- Multi-omics analysis identifies fibroblast IGFBP5 as a key target of anti-TNFα therapy in ulcerative colitis.Frontiers in immunology · 2026Article
- Pathologic Signaling and Disease Implications of Insulin-like Growth Factor Binding Proteins in Cancer, Cardiovascular Disease, and Fibrosis.International journal of molecular sciences · 2025Review
- FAM20C: A key protein kinase in multiple diseases.Genes & diseases · 2025Review
- Role and mechanism of IGFBP5 in the real-ambient particulate matter exposure-induced chronic lung injury.Frontiers in pharmacology · 2025Article
- SPP1+ macrophages promote head and neck squamous cell carcinoma progression by secreting TNF-α and IL-1β.Journal of experimental & clinical cancer research : CR · 2024Article
- Expression of insulin-like growth factor binding protein 5 in the vaginal wall tissues of older women with pelvic organ prolapse.Scientific reports · 2024Article
- Identification of key genes associated with cervical cancer based on bioinformatics analysis.BMC cancer · 2024Article
- Secreted insulin-like growth factor binding protein 5 functions as a tumor suppressor and chemosensitizer through inhibiting insulin-like growth factor 1 receptor/protein kinase B pathway in acute myeloid leukemia.Neoplasia (New York, N.Y.) · 2024Article
- Comprehensive Analyses and Experiments Confirmed IGFBP5 as a Prognostic Predictor Based on an Aging-genomic Landscape Analysis of Ovarian Cancer.Current cancer drug targets · 2024Article
- Identification of disulfidptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in colorectal cancer.Journal of cancer research and clinical oncology · 2023Article
- Article
- Insulin-like growth factor binding protein 5b ofFrontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to investigate the role of IGFBP5 in colorectal cancer (CRC) and the relationship between the expression of IGFBP5 and clinicopathological parameters in CRC patients. Patients and Methods: Immunohistochemical analysis was used to detect the expression of IGFBP5 and its correlation with clinicopathological parameters of CRC patients. Prognosis analysis, gene set enrichment analysis, and protein interaction network analysis were performed using bioinformatics analysis. The Genomics of Drug Sensitivity in Cancer (GDSC) dataset was used to analyze the correlation between the expression of IGFBP5 and drug resistance. Results: Immunohistochemical analysis revealed that the expression of IGFBP5 was significantly higher in CRC tissues than in para-cancerous tissues (P < 0.05). High expression of IGFBP5 was associated with tumor differentiation and the N stage of CRC (P < 0.05). Moreover, high expression of IGFBP5 predicted worse overall survival and disease-free survival in CRC patients (P < 0.05). The expression of IGFBP5 was associated with cell-matrix adhesion, extracellular matrix binding, and collagen binding (P < 0.05). Furthermore, IGFBP5 was involved in the Hedgehog signaling pathway and PI3K-Akt signaling pathway (P < 0.05). IGF1, IGF2, SPP1, LTBP1, and FAM20C were most closely related to IGFBP5. Conclusion: The expression of IGFBP5 is upregulated and associated with tumor differentiation, lymph node metastasis, drug resistance, and prognosis in CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.